NCT01776554View on ClinicalTrials.gov

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

PHASE2CompletedINTERVENTIONAL
Enrollment

662

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2014

Conditions
Pandemic H5N1 Influenza
Interventions
BIOLOGICAL

Adjuvanted H5N1 pandemic influenza vaccine

Comparison of two doses of aH5N1c vaccine

Trial Locations (12)

10400

75 Phramongkutklao Hospital, Bangkok

76 Faculty of Tropical Medicine Mahidol University, Bangkok

63110

1 Saint Louis University, St Louis

67114

7 Heartland Research Associates, Newton

67207

5 Heartland Research Associates, Wichita

9 Heartland Research Associates, Wichita

68005

3 Meridian Clinical Research, Miami

68134

6 Meridian Clinical Research, Omaha

78745

10 Tekton Research, Georgetown

84109

8 Foothill Family Clinic, Salt Lake City

84121

4 Foothill Family Clinic, South Cottonwood Heights

99204

2 Rockwood Clinic P S, Spokane

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
collaborator

Department of Health and Human Services

FED

lead

Novartis Vaccines

INDUSTRY

NCT01776554 - Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children | Biotech Hunter | Biotech Hunter